Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Ioannou N, et al. Among authors: shanafelt td. Blood. 2021 Jan 14;137(2):216-231. doi: 10.1182/blood.2020006073. Blood. 2021. PMID: 33024998 Free PMC article.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Wang XV, et al. Among authors: shanafelt td. Blood. 2021 Dec 30;138(26):2810-2827. doi: 10.1182/blood.2020010146. Blood. 2021. PMID: 34407545 Free PMC article. Clinical Trial.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Shanafelt TD, et al. Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960. Blood. 2022. PMID: 35427411 Free PMC article. Clinical Trial.
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Shanafelt TD, et al. Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14. Blood. 2013. PMID: 23493782 Free article. Clinical Trial.
How we treat Richter syndrome.
Parikh SA, Kay NE, Shanafelt TD. Parikh SA, et al. Among authors: shanafelt td. Blood. 2014 Mar 13;123(11):1647-57. doi: 10.1182/blood-2013-11-516229. Epub 2014 Jan 13. Blood. 2014. PMID: 24421328 Free PMC article.
The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Schwager SM, Lesnick CE, Kleinstern G, Van Dyke D, Hanson CA, Braggio E, Slager SL, Shanafelt TD. Parikh SA, et al. Among authors: shanafelt td. Blood. 2021 Jul 15;138(2):149-159. doi: 10.1182/blood.2020009813. Blood. 2021. PMID: 33876228 Free PMC article.
425 results